Off-label marketing of medicines in the US is rife but difficult to control, study finds

Despite U.S. Federal Drug Administration regulation of the approval and use of pharmaceutical products, "off-label" marketing of drugs (for purposes other than those for which the drug was approved) has occurred in all aspects of the US health care system. In a new study, researchers report that the most common alleged off-label marketing practices also appear to be the most difficult to control through external regulatory approaches.

Read the whole article on Science Daily

More from Science Daily